RIVASTIGMINE TARTRATE
Clinical safety rating: caution
Other cholinergic agents can have additive effects Can cause nausea vomiting and weight loss.
Reversible, non-competitive inhibitor of acetylcholinesterase and butyrylcholinesterase, increasing acetylcholine concentration in the CNS.
| Metabolism | Primarily metabolized by cholinesterase-mediated hydrolysis; minimal CYP450 involvement. |
| Excretion | Rivastigmine is extensively metabolized by cholinesterase-mediated hydrolysis to the inactive decarbamylated metabolite, NAP226-90, which is then excreted renally. Approximately 97% of a dose is excreted in urine as metabolites (<1% as parent drug), and about 0.4% in feces. Renal elimination accounts for >90% of total clearance. |
| Half-life | The terminal elimination half-life is approximately 1.5 hours after oral administration. However, due to slow dissociation from the cholinesterase enzyme, the pharmacodynamic half-life (duration of enzyme inhibition) is about 10 hours, supporting twice-daily dosing. |
| Protein binding | Approximately 40% bound to plasma proteins (primarily albumin). Binding is concentration-independent over therapeutic range. |
| Volume of Distribution | Apparent volume of distribution (Vd/F) is 1.8–2.7 L/kg, indicating extensive tissue distribution and penetration across the blood-brain barrier. |
| Bioavailability | Oral: Absolute bioavailability is approximately 36% due to first-pass metabolism; food increases Cmax by 60% and AUC by 30% (take with meals). Transdermal: Bioavailability is about 50% relative to oral, with lower peak-to-trough fluctuations. |
| Onset of Action | Oral: Clinical effects (e.g., cognitive improvement) are typically observed after multiple doses, but central cholinesterase inhibition begins within 1–2 hours of a single dose. Transdermal: Therapeutic plasma levels are reached within 8–16 hours after patch application, with steady-state achieved by 24 hours. |
| Duration of Action | Oral: Duration of acetylcholinesterase inhibition in the CNS persists for about 10 hours, supporting twice-daily dosing. The clinical effect on cognition is sustained with consistent dosing but does not alter disease progression. Transdermal: The 24-hour patch maintains steady-state plasma concentrations and continuous enzyme inhibition throughout the day. |
Initial 1.5 mg orally twice daily; increase by 1.5 mg twice daily at ≥2-week intervals to maximum 6 mg twice daily if tolerated.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; use with caution in severe renal impairment (CrCl <10 mL/min). |
| Liver impairment | Child-Pugh A or B: no adjustment. Child-Pugh C: reduce dose or increase dosing interval (e.g., start at 1.5 mg twice daily and titrate slowly). |
| Pediatric use | Not FDA approved for pediatric use; limited data. In clinical trials, oral dose of 0.03–0.06 mg/kg twice daily titrated to maximum 0.12 mg/kg twice daily. |
| Geriatric use | Same as adult dosing; monitor for adverse effects (GI, bradycardia) due to age-related changes. Start at low end of dosing range. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other cholinergic agents can have additive effects Can cause nausea vomiting and weight loss.
| FDA category | Animal |
| Breastfeeding | Excreted in rat milk; unknown in human milk. M/P ratio not available. Caution advised; decide whether to discontinue nursing or the drug, considering importance to mother. |
| Teratogenic Risk | Pregnancy Category B. Animal studies at doses up to 2.3 mg/kg/day (approximately 6 times the maximum human dose) showed no teratogenicity. However, no adequate and well-controlled studies in pregnant women. Use only if clearly needed. First trimester: no specific malformations reported; second and third trimesters: consider potential for increased cholinergic effects. |
■ FDA Black Box Warning
No FDA boxed warning.
| Common Effects | Parkinson's disease dementia |
| Serious Effects |
["Hypersensitivity to rivastigmine or any excipients","History of application site reactions with rivastigmine patch"]
| Precautions | ["Gastrointestinal adverse reactions (nausea, vomiting, diarrhea, anorexia, weight loss)","Syncope and bradycardia due to vagotonic effects","Exacerbation of extrapyramidal symptoms in Parkinson's disease","Risk of gastrointestinal bleeding","Use with caution in patients with sick sinus syndrome or other conduction abnormalities"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required; standard prenatal care. Monitor for cholinergic adverse effects (e.g., nausea, vomiting, diarrhea) which may affect maternal hydration and nutrition. |
| Fertility Effects | No human data on fertility. In animal studies, no effects on fertility at doses up to 2.3 mg/kg/day. |